AcelRx Pharmaceuticals (ACRX) Trading Up 8.6%

AcelRx Pharmaceuticals (NASDAQ:ACRX) shares were up 8.6% during trading on Wednesday . The company traded as high as $3.15 and last traded at $3.15. Approximately 820,741 shares were traded during mid-day trading, an increase of 79% from the average daily volume of 457,370 shares. The stock had previously closed at $2.90.

A number of research analysts have recently commented on ACRX shares. Zacks Investment Research upgraded AcelRx Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.75 target price for the company in a research note on Tuesday, May 15th. ValuEngine upgraded AcelRx Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Wednesday, May 2nd. One research analyst has rated the stock with a sell rating, three have issued a hold rating and five have given a buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $4.96.

The company has a market cap of $161.66 million, a P/E ratio of -2.93 and a beta of 2.38. The company has a debt-to-equity ratio of -0.20, a current ratio of 4.05 and a quick ratio of 4.00.



AcelRx Pharmaceuticals (NASDAQ:ACRX) last released its earnings results on Wednesday, May 9th. The specialty pharmaceutical company reported ($0.23) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.24) by $0.01. The firm had revenue of $0.34 million during the quarter, compared to analysts’ expectations of $0.78 million. analysts forecast that AcelRx Pharmaceuticals will post -0.85 earnings per share for the current year.

Hedge funds have recently bought and sold shares of the stock. Geller Family Office Services LLC increased its position in AcelRx Pharmaceuticals by 175.0% during the 4th quarter. Geller Family Office Services LLC now owns 275,000 shares of the specialty pharmaceutical company’s stock valued at $557,000 after buying an additional 175,000 shares in the last quarter. Virtu Financial LLC bought a new position in AcelRx Pharmaceuticals during the 4th quarter valued at approximately $120,000. Northern Trust Corp increased its position in AcelRx Pharmaceuticals by 60.8% during the 1st quarter. Northern Trust Corp now owns 91,481 shares of the specialty pharmaceutical company’s stock valued at $192,000 after buying an additional 34,584 shares in the last quarter. Finally, GSA Capital Partners LLP bought a new position in AcelRx Pharmaceuticals during the 1st quarter valued at approximately $113,000. 8.94% of the stock is owned by institutional investors.

About AcelRx Pharmaceuticals

AcelRx Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain.

Receive News & Ratings for AcelRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply